Our comprehensive study on IFI30 in gliomas found its expression to be high in glioblastomas and in gliomas with a mesenchymal subtype or wild‐type isocitrate dehydrogenase, all of which indicated the malignancy and poor outcomes of gliomas. This evidence concerns the gene IDH3A and central nervous system cancer.